Tern invests in Talking Medicines convertible loan notes By Investing.com

Tern issued about £270,000 of convertible loan notes in Talking Medicines, funded by canceling roughly £87,000 of debt and investing about £48,000 of new cash. The notes pay 10% interest and convert at a 20% discount on an exit or fundraising of at least £2 million; otherwise they mature on November 21, 2029. Tern’s equity stake stays unchanged at 23.8%, while total convertible holdings in Talking Medicines rise to about £790,000.

Analysis

This is less a financing event than a structured mark-up of a long-dated illiquid claim. The economics imply Tern is effectively extending follow-on support to avoid crystallizing a weak valuation while increasing exposure at a paper basis that is roughly twice the cash outlay plus debt forgiveness, which is a classic way to defend headline NAV in a private portfolio. The key second-order effect is that the valuation is now more sensitive to the next priced equity round than to operating performance, because the conversion discount converts any future financing into an embedded revaluation option.

For Talking Medicines, the cost of capital is now punitive: 10% cash yield plus a 20% conversion discount means dilution risk is being pulled forward into the next fundraise, even if the company survives to 2029. That structure can create a perverse incentive to keep raising small, bridge-style rounds rather than pursuing a true scaling event, which often compresses enterprise value over time as new money is effectively paying off old capital rather than funding growth. Competitively, that favors better-capitalized AI healthcare advertising platforms that can hire and scale without signaling distress.

The contrarian read is that this is not necessarily a positive for Tern equity, despite the apparent uplift in implied asset value. Repeated insider-style refinancing of a subscale private asset often masks portfolio concentration risk and delays loss recognition; the market usually punishes that once cash burn or insolvency becomes impossible to ignore. The relevant catalyst window is 6-18 months: either a qualifying fundraise validates the mark or the asset remains trapped in extension mode, in which case the debt becomes a drag on fund-level liquidity rather than a source of optionality.

Key Decisions for Investors

• Tern: avoid or underweight on any strength for the next 3-6 months; this kind of financing typically supports NAV optics before it helps cash realization, so downside is better expressed if the stock re-rates on headline optimism.
• If accessible, pair long higher-quality private-markets compounders with disciplined mark policies against Tern-style venture holding companies; the relative trade is that transparent capital allocation should outperform as public investors penalize opaque refinancing risk over 6-12 months.
• For venture/AI healthcare exposure, favor cash-generative infrastructure or workflow names over adtech-dependent platforms; the setup implies that customer acquisition and data science claims are easy to fund but hard to monetize in a tightening capital regime.
• Watch for a priced equity round at Talking Medicines within 6-12 months; if the valuation is flat/down and the round is small, that would confirm the asset is being extended rather than scaled, a negative catalyst for Tern's reported book value.